StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com

Phio Pharmaceuticals Gets Nasdaq Notice Over Sub-$1 Share Price

Phio Pharmaceuticals said Nasdaq notified it that its stock had closed below $1.00 for 30 consecutive business days, giving it until May 17, 2027 to regain compliance.

What happened

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) said it received written notice on November 16, 2026 from Nasdaq's Listing Qualifications Department stating that the bid price for its common stock had closed below $1.00 per share for the previous 30 consecutive business days, according to a Form 8-K filed November 20, 2026.

The notice cites Nasdaq Listing Rule 5550(a)(2), the exchange's minimum bid price requirement, and has no immediate effect on the listing or trading of Phio's common stock.

The company said it will monitor its closing bid price and evaluate options to regain compliance. The filing does not state what specific steps it plans to take.

The compliance window

Under Nasdaq Listing Rule 5810(c)(3)(A), Phio has an initial 180 calendar days, until May 17, 2027, to regain compliance. If the closing bid price is at least $1.00 per share for a minimum of 10 consecutive business days before that date, Nasdaq will notify the company that it has regained compliance, according to the filing.

The stock closed at $0.656 on the event date, down 8.25% from the prior close of $0.715, according to the price data.

What this means

Phio is a pharmaceutical company incorporated in Delaware and listed on the Nasdaq Capital Market under the ticker PHIO. The Nasdaq Capital Market is the exchange's tier most commonly used by smaller companies.

A minimum bid price rule is a listing standard, not a judgment about the company's finances. Nasdaq requires that a listed stock trade at or above $1.00; if it stays below that level for 30 consecutive business days, the exchange's listing qualifications staff issues a deficiency notice.

The notice is disclosed under Item 3.01 of Form 8-K, the item that covers delisting notices and failures to satisfy continued listing rules. Filing an 8-K is how a public company formally reports certain material events to the Securities and Exchange Commission; this one was signed by President and CEO Robert J. Bitterman.

The 180-day cure period is the standard first step. Regaining compliance is typically achieved either by the share price rising back above $1.00 on its own, or through a corporate action such as a reverse stock split, which reduces the number of shares outstanding and raises the per-share price proportionally. Phio's filing does not say whether it is considering a reverse split or any other measure; it states only that it will evaluate options.

A reverse split changes the share count and price but not the value of a holder's stake at the moment of the split, and it requires shareholder approval. If a company does not regain compliance within the initial 180-day window, Nasdaq rules provide for a possible second compliance period, subject to exchange review, before any delisting action. The filing does not address that possibility.

The company also included standard forward-looking language, noting that statements about its ability to regain compliance are predictions and that actual results may differ.

Sources

Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.